SEQUENTPharmaceuticals
Sequent Scientific Ltd — Cash Flow Statement
₹188.78
+0.00%
Sequent Scientific Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Capital Expenditure | -39.09 Cr | -30.81 Cr | -86.18 Cr | -32.46 Cr | — |
| End Cash Position | 62.66 Cr | 64.81 Cr | 41.57 Cr | 57.50 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 40000.00 | — | — | 1.47 Cr | — |
| Beginning Cash Position | 64.81 Cr | 41.57 Cr | 57.50 Cr | 53.74 Cr | — |
| Changes In Cash | -2.15 Cr | 23.24 Cr | -15.92 Cr | 2.29 Cr | — |
| Financing Cash Flow | -60.73 Cr | -1.44 Cr | 32.23 Cr | 67.26 Cr | — |
| Interest Paid Cff | -51.28 Cr | -45.35 Cr | -35.57 Cr | -16.21 Cr | — |
| Net Common Stock Issuance | 7.45 Cr | 0.00 | 0.00 | 11.25 Cr | — |
| Common Stock Issuance | 7.45 Cr | 0.00 | 0.00 | 11.25 Cr | — |
| Net Issuance Payments Of Debt | -2.61 Cr | 54.81 Cr | 77.67 Cr | 91.11 Cr | — |
| Net Short Term Debt Issuance | -82.89 Cr | 58.42 Cr | 55.75 Cr | 54.92 Cr | — |
| Net Long Term Debt Issuance | 80.28 Cr | -3.62 Cr | 21.92 Cr | 36.19 Cr | — |
| Long Term Debt Payments | -187.90 Cr | -58.47 Cr | -35.63 Cr | -31.31 Cr | — |
| Long Term Debt Issuance | 268.19 Cr | 54.85 Cr | 57.54 Cr | 67.50 Cr | — |
| Investing Cash Flow | -24.78 Cr | -5.92 Cr | -64.96 Cr | -95.57 Cr | — |
| Net Other Investing Changes | -20000.00 | 13.38 Cr | — | — | — |
| Interest Received Cfi | 2.46 Cr | 0.57 Cr | 1.23 Cr | 0.28 Cr | — |
| Net Investment Purchase And Sale | 2.15 Cr | -8.22 Cr | 23.76 Cr | 3.75 Cr | — |
| Net PPE Purchase And Sale | -29.39 Cr | -11.65 Cr | -74.51 Cr | -31.27 Cr | — |
| Sale Of PPE | 9.70 Cr | 19.15 Cr | 11.67 Cr | 1.19 Cr | — |
| Purchase Of PPE | -39.09 Cr | -30.81 Cr | -86.18 Cr | -32.46 Cr | — |
| Operating Cash Flow | 83.36 Cr | 30.59 Cr | 16.81 Cr | 30.59 Cr | — |
| Taxes Refund Paid | -27.61 Cr | -14.06 Cr | -14.64 Cr | -26.77 Cr | — |
| Change In Working Capital | -88.38 Cr | -45.67 Cr | -51.61 Cr | -89.30 Cr | — |
| Change In Other Current Assets | -0.01 Cr | -0.04 Cr | 1.58 Cr | 0.69 Cr | — |
| Change In Payable | 6.43 Cr | -37.14 Cr | -17.01 Cr | 65.47 Cr | — |
| Change In Inventory | -46.86 Cr | 0.29 Cr | 5.08 Cr | -114.73 Cr | — |
| Change In Receivables | -47.94 Cr | -8.78 Cr | -41.26 Cr | -40.72 Cr | — |
| Other Non Cash Items | 54.14 Cr | 49.81 Cr | 119.16 Cr | 15.14 Cr | — |
| Stock Based Compensation | 32.41 Cr | 22.23 Cr | 35.41 Cr | 33.30 Cr | — |
| Provisionand Write Offof Assets | -0.13 Cr | 1.38 Cr | 0.76 Cr | -0.01 Cr | — |
| Depreciation And Amortization | 66.45 Cr | 61.54 Cr | 55.69 Cr | 51.54 Cr | — |
| Amortization Cash Flow | 11.80 Cr | 10.56 Cr | 10.50 Cr | 7.40 Cr | — |
| Depreciation | 54.65 Cr | 50.98 Cr | 45.20 Cr | 44.14 Cr | — |
| Gain Loss On Investment Securities | -0.15 Cr | -0.04 Cr | -0.05 Cr | -0.48 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 8.05 Cr | 15.37 Cr | 11.45 Cr | -6.30 Cr | — |
| Gain Loss On Sale Of PPE | -6.02 Cr | -5.54 Cr | -2.04 Cr | 0.07 Cr | — |
| Net Income From Continuing Operations | 44.31 Cr | -54.65 Cr | -137.66 Cr | 52.93 Cr | — |
| Free Cash Flow | 44.27 Cr | -0.21 Cr | -69.37 Cr | -1.87 Cr | — |
| Repayment Of Debt | -187.90 Cr | -58.47 Cr | -35.63 Cr | -31.31 Cr | — |
| Issuance Of Debt | 268.19 Cr | 54.85 Cr | 57.54 Cr | 67.50 Cr | — |
| Issuance Of Capital Stock | 7.45 Cr | 0.00 | 0.00 | 11.25 Cr | — |
| Net Other Financing Charges | — | 90000.00 | — | — | 0.01 Cr |
| Dividends Received Cfi | — | 0.00 | 10000.00 | 0.15 Cr | 0.93 Cr |
| Sale Of Investment | — | 0.00 | 23.76 Cr | 3.75 Cr | 193.07 Cr |
| Purchase Of Investment | — | -8.22 Cr | 0.00 | — | -140.48 Cr |
| Net Business Purchase And Sale | — | 0.00 | -15.44 Cr | -68.47 Cr | -140.48 Cr |
| Purchase Of Business | — | 0.00 | -15.44 Cr | -68.47 Cr | -140.48 Cr |
| Common Stock Dividend Paid | — | — | 0.00 | -12.34 Cr | — |
| Cash Dividends Paid | — | — | — | -12.34 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sequent Scientific Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.